Deferasirox (Exjade®) for the treatment of iron overload

Research output: Contribution to journalArticlepeer-review


Deferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload. The clinical development program has demonstrated the efficacy of deferasirox for up to 4.5 years of treatment in patients with various underlying anemias, including β-thalassemia, myelodysplastic syndromes, sickle cell disease, aplastic anemia, and other rare anemias. In addition to reducing key indicators of total body iron levels (serum ferritin, liver iron concentration, and toxic labile plasma iron), deferasirox has also demonstrated the ability to remove cardiac iron and prevent future cardiac iron accumulation. Emerging long-term data confirm the tolerability profile of deferasirox, and data on patient compliance render deferasirox a suitable therapeutic option for patients with chronic conditions requiring ongoing iron chelation therapy. Data continue to accumulate in a wide range of patient groups, including those with non-transfusion-dependent anemias such as hereditary hemochromatosis.

Original languageEnglish
Pages (from-to)165-173
Number of pages9
JournalActa Haematologica
Issue number2-3
Publication statusPublished - Nov 2009


  • Chelation
  • Deferasirox
  • Myelodysplastic syndromes
  • Pediatric anemia
  • Sickle cell disease
  • Thalassemia

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Deferasirox (Exjade®) for the treatment of iron overload'. Together they form a unique fingerprint.

Cite this